Relay Therapeutics (RLAY)
NASDAQ:RLAY
Want to see RLAY full AI Analyst Report?
RLAY Stock Chart & Stats
$16.76
>-$0.01(-0.22%)
At close: 4:00 PM EST
$16.76
>-$0.01(-0.22%)
Day’s Range― - ―
52-Week Range$2.53 - $15.89
Previous CloseN/A
Volume391.09K
Average Volume (3M)3.11M
Market Cap
$2.77B
Enterprise Value$2.94B
Total Cash (Recent Filing)$554.52M
Total Debt (Recent Filing)$32.46M
Price to Earnings (P/E)―
Beta2.21
Next Earnings
Apr 30, 2026EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding178,725,810
10 Day Avg. Volume4,201,481
30 Day Avg. Volume3,112,398
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)2.56
Price to Sales (P/S)94.54
P/FCF Ratio-6.15
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue191.71
Enterprise Value/Gross Profit210.14
Enterprise Value/Ebitda-10.12
Forecast
1Y Price Target
$18.29Price Target Upside9.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.53
Revenue Forecast (FY)$5.84M
Bulls Say, Bears Say
Bulls Say
Clinical Development And Regulatory PathwayA planned pivotal Phase III head-to-head trial against the market leader creates a clear regulatory pathway that could enable label expansion and commercialization if trial endpoints are met.
Clinical EfficacyEarly clinical data showing higher response rates and longer progression-free survival for zovegalisib versus a competing PI3Kα inhibitor suggest the drug could offer meaningful clinical differentiation in relevant breast cancer patients.
Financial Position And RunwayA substantial cash balance expected to fund operations through multiple key clinical milestones reduces near-term financing risk and supports continued development execution.
Bears Say
Clinical Safety RiskSafety results from the vascular malformation program are likely to determine whether zovegalisib advances in that indication or prompts a strategic pivot, creating meaningful program-level risk.
Competitive Landscape And Partner RiskProgress by large pharmaceutical competitors and a major partner running its own head-to-head study increases competitive and collaboration risk that could limit Relay's market opportunity for first-line programs.
Market Sentiment And Valuation VulnerabilityA strong share-price run has elevated investor expectations around upcoming readouts, leaving the stock vulnerable to sharp declines from modest adverse safety or efficacy signals.
Relay Therapeutics News
RLAY FAQ
What was Relay Therapeutics’s price range in the past 12 months?
Relay Therapeutics lowest stock price was $2.53 and its highest was $15.89 in the past 12 months.
What is Relay Therapeutics’s market cap?
Relay Therapeutics’s market cap is $2.77B.
When is Relay Therapeutics’s upcoming earnings report date?
Relay Therapeutics’s upcoming earnings report date is Apr 30, 2026 which is in 11 days.
How were Relay Therapeutics’s earnings last quarter?
Relay Therapeutics released its earnings results on Feb 26, 2026. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.405 by $0.085.
Is Relay Therapeutics overvalued?
According to Wall Street analysts Relay Therapeutics’s price is currently Undervalued.
Does Relay Therapeutics pay dividends?
Relay Therapeutics does not currently pay dividends.
What is Relay Therapeutics’s EPS estimate?
Relay Therapeutics’s EPS estimate is -0.36.
How many shares outstanding does Relay Therapeutics have?
Relay Therapeutics has 178,725,810 shares outstanding.
What happened to Relay Therapeutics’s price movement after its last earnings report?
Relay Therapeutics reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.405. Following the earnings report the stock price went up 12.009%.
Which hedge fund is a major shareholder of Relay Therapeutics?
Currently, no hedge funds are holding shares in RLAY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Relay Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.29 (9.13% Upside)
$18.29 (9.13% Upside)
Blogger Sentiment
Bullish
RLAY Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $386.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.8%
Last 30 Days ▲ 12.0%
Last 30 Days ▲ 12.0%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
517.24%
12-Months-Change
Fundamentals
Return on Equity
-43.17%
Trailing 12-Months
Asset Growth
-28.69%
Trailing 12-Months
Company Description
Relay Therapeutics
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
RLAY Stock 12 Month Forecast
Average Price Target
$18.29
▲(9.13% Upside)
Technical Analysis
Ownership Overview
2.32% Insiders
9.52% Mutual Funds
0.52% Other Institutional Investors
74.86% Public Companies and Individual Investors